Show results for
Refine by
Clinical Outcomes Equipment Supplied In Canada
6 equipment items found
Manufactured by:Augurex Life Sciences Corp. based inVancouver, BRITISH COLUMBIA (CANADA)
In particular, they are highly specific in very early RA and increase the patient identification rate into the 90% range. Early RA diagnosis and treatment improves clinical outcomes and 14-3-3η protein and its auto-antibodies supports that clinical ...
Manufactured by:Delfi Medical Innovations Inc based inVancouver, BRITISH COLUMBIA (CANADA)
Delfi’s patented Limb Occlusion Pressure (LOP) technology allows a patient specific LOP to be measured and automatically calculates the patient’s Personalized Tourniquet Pressure (PTP) as percentage of ...
Manufactured by:Synaptive Medical based inToronto, ONTARIO (CANADA)
Experience Modus X, a robotic exoscope featuring advanced 4K 3D optics and fluorescence visualization for neurosurgery, spine, ENT, and reconstructive ...
Manufactured by:Augurex Life Sciences Corp. based inVancouver, BRITISH COLUMBIA (CANADA)
Citrullination is a highly relevant post-translational modification of proteins that occurs in RA and certain other conditions. In the extracellular space, 14-3-3η becomes citrullinated (cit) in the presence of peptidylarginine deiminases (PAD) enzymes and this extracellular modified form of the protein, cit-14-3-3η, also elicits an auto-immune response that generates cit-14-3-3η ...
Manufactured by:Augurex Life Sciences Corp. based inVancouver, BRITISH COLUMBIA (CANADA)
In the development of RA and other inflammatory types of arthritis, multiple factors contribute to disease processes to varying degrees in different patients. 14-3-3η is recognized as a new factor within this process and represents a rationale drug target for personalized medicine alongside its 14-3-3η companion biomarker portfolio described above. Augurex preclinical animal studies to ...
Manufactured by:Augurex Life Sciences Corp. based inVancouver, BRITISH COLUMBIA (CANADA)
Extracellular 14-3-3η protein is a potent ligand and activator of intracellular signalling pathways that lead to the up-regulation of inflammation and joint damage factors involved in RA pathogenesis. The 14-3-3η blood test is clinically available as a diagnostic test whereby a positive result indicates a 5 to 50 times greater likelihood of having RA and informs joint damage prognosis and ...